Daesung Microbiological Labs. Co., Ltd. Stock: price and insider trades · South Korea
대성미생물
No insider purchase over the last 90 days. The latest, by 인실리코, was filed 04 Jun 2026.
Daesung Microbiological Labs. Co., Ltd.: what insiders have been doing
This page follows insider dealings at Daesung Microbiological Labs. Co., Ltd. as filed with DART (FSS), a company from the Health Care sector. The last twelve months, up to 23 October 2026, brought 17 filings signed by 3 insiders.
On the market, 2 insiders bought (14 purchases totalling €16.7M) while 1 insider sold (1 sale totalling €7.1M). The totals exclude 5 filings filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 인실리코 filed the largest purchase, €9.3M, on 29 May 2026. The buyers include 1 chief executive.
Compared with its exchange (2,650 companies, median 7 filings), a count of 17 filings is above the norm. The full history, which starts in 2024, counts 16 purchases against 1 sale.
The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 4 June 2026, 159 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 1 day. The shorter that gap, the sooner other investors can see what insiders have done.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -5.9%Entry ₩6,630 · Close at T+90 ₩6,240
- -14.4%Entry ₩6,510 · Close 23 Oct 2026 ₩5,570
- -23.4%Entry ₩9,990 · Close at T+365 ₩7,650
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 13,658 shares@ ₩6,606.000.35% mcap0.3% of flowShareKRXDART:20260604000093Canonical exit: 2 Sept 2026 (T+90)
- 8,688 shares@ ₩6,642.000.22% mcap0.2% of flowShareKRXDART:20260602000091Canonical exit: 31 Aug 2026 (T+90)
- 6,468 shares@ ₩6,682.000.17% mcap0.1% of flowShareKRXDART:20260601000469Canonical exit: 30 Aug 2026 (T+90)
- 4,027 sharesShareKRXDART:20260601000385Canonical exit: 30 Aug 2026 (T+90)
- 1,134 shares@ ₩6,800.000.030% mcap14.9% of flowShareKRXDART:20260529001220Canonical exit: 26 Aug 2026 (T+90)
- 9,086 shares@ ₩6,746.000.24% mcap0.2% of flowShareKRXDART:20260529001126Canonical exit: 27 Aug 2026 (T+90)
- 3,500 shares@ ₩6,750.000.093% mcap45.6% of flowShareKRXDART:20260529001235Canonical exit: 27 Aug 2026 (T+90)
- 1,466,740 shares@ ₩11,000.0064.18% mcap55.8% of flowShareKRXDART:20260529001008Canonical exit: 22 Jun 2026 (T+90)
- 3,149 sharesShareKRXDART:20260526000150Canonical exit: 24 Aug 2026 (T+90)
- 5,476 sharesShareKRXDART:20260522000268Canonical exit: 20 Aug 2026 (T+90)
- 9,614 sharesShareKRXDART:20260522000111Canonical exit: 20 Aug 2026 (T+90)
- 8,000 sharesShareKRXDART:20260521000081Canonical exit: 19 Aug 2026 (T+90)
- 3,000 shares@ ₩6,810.000.091% mcap39.5% of flowShareKRXDART:20260515001671Canonical exit: 13 Aug 2026 (T+90)
- 0KRXDART:20260325001434
- 1,466,740 shares49.01% mcap100.0% of flowKRXDART:20260325001437
- 0KRXDART:20260313000989
- 1,466,740 shares49.90% mcap43.4% of flowKRXDART:20260313001062Canonical exit: 7 Jun 2026 (T+90)
- ShareKRXDART:20240826000064Canonical exit: 19 Nov 2024 (T+90)
- 1,320,066 sharesKRXDART:20240826000075Canonical exit: 19 Nov 2024 (T+90)
19 of 19 declarations
About Daesung Microbiological Labs. Co., Ltd.
대성미생물 is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development and production of microbiological products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
